MACULAR DEGENERATION — GENETIC RISK

Macular Degeneration Genetic Risk — AMD has approximately 70% heritability, and complement-targeted therapies for geographic atrophy are now FDA-approved, with genetic complement variant status potentially guiding treatment selection.

Whole genome sequencing evaluates all AMD-associated genes — CFH, ARMS2/HTRA1, C3, CFB, C2, CFI, TIMP3 — providing the genetic risk profile that informs screening intensity, lifestyle modification urgency, and eligibility for complement-targeted therapies.

CLIA CertifiedCAP AccreditedISO 15189 Medical LabACMG ClassifiedHIPAA & GDPR100,000+ Genomes Sequenced

About this condition

Macular Degeneration — Genetic Risk

Age-related macular degeneration (AMD) is the leading cause of central vision loss in adults over 50, affecting approximately 11 million Americans. AMD has one of the highest heritabilities of any common disease — approximately 46-71%. The complement factor H (CFH) Y402H variant (rs1061170) on chromosome 1q31.3 is the strongest single genetic risk factor: carriers have approximately 2.5-7x increased risk depending on genotype (heterozygous ~2.5x, homozygous ~5-7x). The second major locus is ARMS2/HTRA1 on chromosome 10q26, conferring ~2.5-3x risk per allele. Together, CFH and ARMS2/HTRA1 explain approximately 50% of AMD heritability.

The complement pathway has become a therapeutic target for AMD. Pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay), both complement inhibitors (C3 and C5 inhibitors respectively), received FDA approval in 2023 for geographic atrophy (GA) — the advanced dry form of AMD for which no treatment previously existed. These complement-targeted therapies slow GA progression by approximately 20-30%. Genetic complement variant status (CFH, C3, CFB genotypes) may influence treatment response — preliminary evidence suggests that patients with certain CFH risk genotypes may have differential complement inhibitor responses, though this pharmacogenomic application is still being validated.

Additional AMD susceptibility genes include C3 (complement component 3, rare risk variants with strong effect), CFB (complement factor B), C2 (complement component 2), CFI (complement factor I), TIMP3 (tissue inhibitor of metalloproteinases 3 — also causes Sorsby fundus dystrophy, a monogenic AMD mimic), ABCA4 (Stargardt disease — can mimic AMD in adults), and BEST1 (Best disease — another AMD mimic). Distinguishing polygenically-driven AMD from monogenic macular dystrophies that mimic AMD (Stargardt, Sorsby, Best disease) has important implications — monogenic conditions have specific treatments, earlier onset, and Mendelian recurrence risks.

Complement inhibitors (pegcetacoplan, avacincaptad) are the first FDA-approved treatments for geographic atrophy — the advanced dry AMD for which no treatment existed before 2023. CFH genotype may predict treatment response.

Gene locus
CFH (1q31.3), ARMS2/HTRA1 (10q26.13), C3 (19p13.3), CFB (6p21.33), CFI (4q25), TIMP3 (22q12.3), ABCA4 (1p22.1)

AMD is the leading cause of central vision loss with 70% heritability. Complement-targeted therapies are now available, and genetic risk profiling guides screening intensity, lifestyle intervention urgency, and may predict therapy response.

CFH genotype may predict complement inhibitor response — precision AMD therapy is emerging

Preliminary pharmacogenomic data suggests that AMD patients with specific CFH, C3, and CFB genotypes may respond differently to complement-targeted therapies. While these associations are still being validated in clinical trials, establishing a patient's complement gene genotype through WGS provides the genetic data needed for future pharmacogenomic-guided AMD therapy selection. Additionally, high-risk CFH genotypes identify individuals who benefit most from aggressive modifiable risk factor management (smoking cessation, AREDS2 supplementation, blood pressure control).

Monogenic macular dystrophies (Stargardt, Best, Sorsby) mimic AMD but have different treatments and genetic counseling implications

Adult-onset Stargardt disease (ABCA4), Best disease (BEST1), and Sorsby fundus dystrophy (TIMP3) can present with macular degeneration clinically indistinguishable from AMD. These monogenic conditions have Mendelian inheritance (50% risk to offspring for dominant conditions), potentially different treatment responses, and — for Stargardt — eligibility for emerging gene therapy trials. WGS distinguishes these monogenic mimics from typical polygenic AMD, enabling accurate genetic counseling and appropriate treatment selection.

Others in Rare Diseases

Browse all conditions →

One test. A lifetime of answers.

One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.

From $449

Ships within 48 hours · Results in 6–8 weeks

Get my Genome Test